Insulin Secretion in Diabetes Before and After Glycemic Control

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes. In particular the effects of signals released from the intestine to stimulate insulin secretion will be tested. Patients with type 2 diabetes will have insulin secretion in response to glucose and intestinal factors before and after insulin treatment to lower their blood glucose. It is expected that the results of this work will provide valuable information for treating diabetic people.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Incretins; Insulin; Insulin Glargine; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Aim 1:

• (non-diabetics)

• male/female 30-65 yrs old,

• free of active medical disease,

• no history of diabetes.

• (diabetics)

• HbA1c=6.5-8.5,

• treated with metformin, a sulfonylurea, or combination,

• Stable body wt with BMI 28-40.

• Aim 2: Same as above

• Aim 3: Diabetic with HgA1c 8.0-9.5

Exclusion Criteria:

• Aim 1: For both groups: no history of: pancreatitis, cardiac, gastrointestinal, renal or liver disease.

• Aim 2: Same as above

• Aim 3: Same as above, plus a diagnosis of incipient diabetic nephropathy severe nonproliferative, or proliferative retinopathy.